文献速递前列腺癌

前列腺特异性膜抗原配体正电子发射断层扫描单发病灶与低前列腺特异性抗原是复发性前列腺癌患者对前列腺特异性膜抗原靶向放射引导手术有利生化反应的预后因素

Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
PubMed 文献 · Eur Urol · 2019-04-12

该研究纳入121例复发性前列腺癌患者(中位PSA 1.13ng/ml),评估PSMA靶向放射引导手术的生化完全缓解率及生化无复发生存期。结果显示66%患者达到生化完全缓解,术前低PSA且单发病灶者生化完全缓解率最高(38/45,84%)。术前低PSA值和PSMA-PET单发病灶与更长的中位生化无复发生存期显著相关。

要点

  • 121例复发性前列腺癌患者接受PSMA靶向放射引导手术,99%(120/121)成功切除转移组织。
  • 66%(77例)达到生化完全缓解(PSA<0.2ng/ml且无需额外治疗)。
  • 术前低PSA且单发病灶者生化完全缓解率最高(38/45,84%),中位生化无复发生存期14.0个月 vs 2.5个月(p=0.002)。

核心结论

  • PSMA靶向放射引导手术可使部分复发性前列腺癌患者获得显著的生化无复发生存期。
  • 术前低PSA值和PSMA配体PET单发病灶患者的生化完全缓解频率和生化无复发生存期最长。

研究设计与样本

  • 连续纳入121例经PSMA配体PET定义的复发性前列腺癌患者(中位PSA 1.13ng/ml),接受PSMA靶向放射引导手术。
  • 评估生化完全缓解(PSA<0.2ng/ml且无需额外治疗)频率及生化无复发生存期,并与术前临床变量进行相关性分析。

主要发现

  • 120/121(99%)患者成功切除转移组织。
  • 77例(66%)达到生化完全缓解。
  • 术前低PSA且单发病灶患者生化完全缓解率最高(38/45,84%)。
  • 全队列中位生化无复发生存期为6.4个月,达到生化完全缓解患者为19.8个月。
  • 术前低PSA值患者中位生化无复发生存期显著更长(p=0.004,风险比1.48,95%置信区间1.13-1.93)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography (PET) allows detection of metastatic prostate cancer (PC) lesions at low prostate-specific antigen (PSA) values. To facilitate their intraoperative detection during salvage surgery, we recently introduced PSMA-targeted radioguided surgery (RGS). OBJECTIVE: To describe the outcome of a large cohort of patients treated with PSMA-targeted RGS and to establish prognostic factors. DESIGN, SETTING, AND PARTICIPANTS: A total of 121 consecutive patients with recurrent PC as defined by PSMA-ligand PET (median PSA: 1.13ng/ml) underwent PSMA-targeted RGS. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The frequency of a complete biochemical response (cBR; PSA <0.2ng/ml) without additional treatment and the duration of biochemical recurrence-free survival (bRFS, time from PSMA-targeted RGS with PSA <0.2ng/ml without further treatment) were evaluated and correlated with preoperatively available clinical variables. RESULTS AND LIMITATIONS: In almost all patients (120/121, 99%) metastatic tissue could be removed. A cBR was achieved in 77 patients (66%). The chance of cBR was highest in patients with both low preoperative PSA and a single lesion (38/45: 84%). Median bRFS was 6.4mo in the whole patient cohort and 19.8mo for patients with cBR. Significantly longer median bRFS was observed in patients with a low preoperative PSA value (p=0.004, hazard ratio 1.48, 95% confidence interval 1.13-1.93) and with a single lesion in preoperative PSMA-ligand PET (14.0 vs 2.5mo, p=0.002). CONCLUSIONS: PSMA-targeted RGS leads to a remarkable interval of bRFS in a subset of patients. The frequency of cBR and the duration of bRFS were highest in patients with a low preoperative PSA value and a single lesion on PSMA-ligand PET. PATIENT SUMMARY: Prostate-specific membrane antigen radioguided surgery delays disease progression in selected patients with recurrent prostate cancer after radical prostatectomy. Patients with a single lesion of recurrence and a low prostate-specific antigen value had the best outcome.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Horn T, Krönke M, Rauscher I, et al. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. Eur Urol. 2019. PMID: 30987843. doi:10.1016/j.eururo.2019.03.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。